Cargando…

Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma

Core needle biopsy (CNB) has been used with caution in pheochromocytoma and paraganglioma (PPGL) due to concerns about catecholamine-related complications. While it is unclear what scientific evidence supports this claim, it has limited the acquisition of biological samples for diagnostic purposes a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Liang, Åkerström, Tobias, Mollazadegan, Kazhan, Beuschlein, Felix, Pacak, Karel, Skogseid, Britt, Crona, Joakim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304911/
https://www.ncbi.nlm.nih.gov/pubmed/37185155
http://dx.doi.org/10.1530/ERC-22-0354
_version_ 1785065611602165760
author Zhang, Liang
Åkerström, Tobias
Mollazadegan, Kazhan
Beuschlein, Felix
Pacak, Karel
Skogseid, Britt
Crona, Joakim
author_facet Zhang, Liang
Åkerström, Tobias
Mollazadegan, Kazhan
Beuschlein, Felix
Pacak, Karel
Skogseid, Britt
Crona, Joakim
author_sort Zhang, Liang
collection PubMed
description Core needle biopsy (CNB) has been used with caution in pheochromocytoma and paraganglioma (PPGL) due to concerns about catecholamine-related complications. While it is unclear what scientific evidence supports this claim, it has limited the acquisition of biological samples for diagnostic purposes and research, especially in metastatic PPGL. We performed a systematic review and individual patient meta-analysis to evaluate the risk of complications after CNB in PPGL patients. The primary and secondary objectives were to investigate the risk of death and the occurrence of complications requiring intervention or hospitalization, respectively. Fifty-six articles describing 86 PPGL patients undergoing CNB were included. Of the patients (24/71), 34% had metastases and 53.4% (31/58) had catecholamine-related symptoms before CNB. Of the patients (14/41), 34.1% had catecholamine excess testing prior to the biopsy. No CNB-related deaths were reported. Four patients (14.8%, 4/27) experienced CNB-related complications requiring hospitalization or intervention. One case had a temporary duodenal obstruction caused by hematoma, two cases had myocardial infarction, and one case had Takotsubo cardiomyopathy. Eight patients (32%, 8/25) had CNB-related catecholamine symptoms, mainly transient hypertension, excessive diaphoresis, tachycardia, or hypertensive crisis. The scientific literature does not allow us to make any firm conclusion on the safety of CNB in PPGL. However, it is reasonable to argue that CNB could be conducted after thorough consideration, preparation, and with close follow-up for PPGL patients with a strong clinical indication for such investigation.
format Online
Article
Text
id pubmed-10304911
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-103049112023-06-29 Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma Zhang, Liang Åkerström, Tobias Mollazadegan, Kazhan Beuschlein, Felix Pacak, Karel Skogseid, Britt Crona, Joakim Endocr Relat Cancer Thematic Research Core needle biopsy (CNB) has been used with caution in pheochromocytoma and paraganglioma (PPGL) due to concerns about catecholamine-related complications. While it is unclear what scientific evidence supports this claim, it has limited the acquisition of biological samples for diagnostic purposes and research, especially in metastatic PPGL. We performed a systematic review and individual patient meta-analysis to evaluate the risk of complications after CNB in PPGL patients. The primary and secondary objectives were to investigate the risk of death and the occurrence of complications requiring intervention or hospitalization, respectively. Fifty-six articles describing 86 PPGL patients undergoing CNB were included. Of the patients (24/71), 34% had metastases and 53.4% (31/58) had catecholamine-related symptoms before CNB. Of the patients (14/41), 34.1% had catecholamine excess testing prior to the biopsy. No CNB-related deaths were reported. Four patients (14.8%, 4/27) experienced CNB-related complications requiring hospitalization or intervention. One case had a temporary duodenal obstruction caused by hematoma, two cases had myocardial infarction, and one case had Takotsubo cardiomyopathy. Eight patients (32%, 8/25) had CNB-related catecholamine symptoms, mainly transient hypertension, excessive diaphoresis, tachycardia, or hypertensive crisis. The scientific literature does not allow us to make any firm conclusion on the safety of CNB in PPGL. However, it is reasonable to argue that CNB could be conducted after thorough consideration, preparation, and with close follow-up for PPGL patients with a strong clinical indication for such investigation. Bioscientifica Ltd 2023-04-26 /pmc/articles/PMC10304911/ /pubmed/37185155 http://dx.doi.org/10.1530/ERC-22-0354 Text en © the author(s) https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Thematic Research
Zhang, Liang
Åkerström, Tobias
Mollazadegan, Kazhan
Beuschlein, Felix
Pacak, Karel
Skogseid, Britt
Crona, Joakim
Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
title Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
title_full Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
title_fullStr Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
title_full_unstemmed Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
title_short Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
title_sort risk of complications after core needle biopsy in pheochromocytoma/paraganglioma
topic Thematic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304911/
https://www.ncbi.nlm.nih.gov/pubmed/37185155
http://dx.doi.org/10.1530/ERC-22-0354
work_keys_str_mv AT zhangliang riskofcomplicationsaftercoreneedlebiopsyinpheochromocytomaparaganglioma
AT akerstromtobias riskofcomplicationsaftercoreneedlebiopsyinpheochromocytomaparaganglioma
AT mollazadegankazhan riskofcomplicationsaftercoreneedlebiopsyinpheochromocytomaparaganglioma
AT beuschleinfelix riskofcomplicationsaftercoreneedlebiopsyinpheochromocytomaparaganglioma
AT pacakkarel riskofcomplicationsaftercoreneedlebiopsyinpheochromocytomaparaganglioma
AT skogseidbritt riskofcomplicationsaftercoreneedlebiopsyinpheochromocytomaparaganglioma
AT cronajoakim riskofcomplicationsaftercoreneedlebiopsyinpheochromocytomaparaganglioma